<DOC>
	<DOCNO>NCT00169143</DOCNO>
	<brief_summary>Evaluation efficacy single injection Pegfilgrastim ( 6mg ) administer day 3 cycle R-ACVBP regimen 4 cycle patient CD20+ diffuse large B-cell lymphoma present least 2 adverse prognostic factor age-adjusted international prognostic index ( Aa-IPI ) .</brief_summary>
	<brief_title>Study R-ACVBP Regimen Supported Pegfilgrastim High-Risk Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This phase II , multicentric , open-label , non-randomized study , evaluate efficacy single injection Pegfilgrastim ( 6mg ) administer day 3 cycle R-ACVBP regimen 4 cycle patient age 18 60 year previously untreated CD20+ diffuse large B-cell lymphoma present least 2 adverse prognostic factor age-adjusted international prognostic index ( Aa-IPI ) , eligible transplant . It anticipate 60 subject enrol 2 year ( 2004 2006 ) , group sequential manner one plan interim analysis . The duration treatment period approximately 26 week patient follow Death . The total Duration study expect 2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large B cell lymphoma ( WHO Classification ) . Age &gt; 18 &lt; 61 year , eligible transplant . Patient previously treat . With least two prognostic factor AaIPI . With minimum life expectancy 3 month . Creatinin level ≤ 150mmol/l , total bilirubin level  30mmol/l transaminase  2.5 maximum normal level , unless abnormality relate lymphoma . Neutrophils &gt; 1.5 G/l platelet &gt; 100 G/l , unless patient bone marrow infiltration . Negative HIV , HBV HCV serologies  4 week ( except vaccination ) . Having previously sign write informed consent . Any histological type lymphoma . Any history treat nontreated indolent lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any history cancer last 5 year , exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Any serious active disease ( accord investigator ’ decision ) . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Pregnant lactate woman woman childbearing potential currently practice adequate method contraception . Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Diffuse large B cell lymphoma</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Autotransplant</keyword>
</DOC>